TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04132830

Intervention type: OTHER
Intervention: In Utero HIV Exposure
Description: Born to mother who had HIV infection during pregnancy.

Intervention type: OTHER
Intervention: No In Utero HIV Exposure
Description: Born to mother who did not have HIV infection during pregnancy.
Study: NCT04154683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio®
Description: use of the Cellvizio® optical biopsy
Study: NCT03798626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 60 mg/mL concentration; administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 60 mg/mL concentration; administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 60 mg/mL concentration; administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 60 mg/mL concentration; administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 25 mg/mL concentration; administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 25 mg/mL concentration; administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 10 mg/mL concentration; administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 6 mg/mL concentration; administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg tablet; administered orally
Study: NCT03287024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGrow Stent System
Description: All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
Study: NCT02978963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT focused on reducing intolerance of uncertainty
Study: NCT01686659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Noninvasive Hemoglobin Monitoring
Description: Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
Study: NCT01824524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
Study: NCT04234399

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluciclovine PET/CT using a digital PET/CT
Description: Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
Study: NCT02055690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Tyrosine Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Tyrosine Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin
Description: Vascular Disrupting Agent
Study: NCT00860964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, calcium 900mg/d, VitD200iu/d and exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
Study: NCT01706081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wait-list
Description: For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
Study: NCT01907204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Oral 32mg/8d-16mg/4d-8mg/4d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide by metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide by nebulization
Study: NCT03144362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Sliding Techniques
Description: Bilateral Sliding Techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Sliding Techniques
Description: Unilateral Sliding Techniques
Study: NCT00757744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
Description: once weekly individual counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug counseling
Description: individual drug counseling
Study: NCT00222430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Use of fluoroscopy during arterial insertion of coronary catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Standard coronary angiography technique; no fluoroscopic assistance
Study: NCT03524690

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Balance
Description: Energy Balance Sufficient food provided to maintain energy balance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Negative Energy Balance
Description: Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
Study: NCT04041466

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AF detection by ECG
Description: Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AF detection by ECG
Description: Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AF detection by ECG
Description: Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
Study: NCT04256668

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Obtaining one or semen samples
Description: Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Obtaining one or semen samples
Description: Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Obtaining one or semen samples
Description: Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
Study: NCT03315104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU-IGIV
Description: Single dose, sterile liquid formulation for IV administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU-IGIV
Description: Single dose, sterile liquid formulation for IV administration.
Study: NCT01973166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Q-switched Laser Treatment
Study: NCT03315104

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for FLU-IGIV
Description: Single dose, normal saline solution for IV administration.
Study: NCT01434394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Erbitux-based chemotherapy
Description: Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Study: NCT02885454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/ethinylestradiol
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
Study: NCT02890329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study: NCT01973166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanosecond Q-switched Laser Treatment
Study: NCT01014650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV or SC dose
Study: NCT02890329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT01696617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 6-week group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 8-week group
Study: NCT06605326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Treprostinil
Description: Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
Study: NCT01014650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV or SC dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: Single IV dose of normal saline
Study: NCT04404751

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Iodised salt with Iron, Folic acid and Vitamin B12
Description: Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Iodised salt with Iron, Folic acid and Vitamin B12
Description: Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Iodised salt with Iron, Folic acid and Vitamin B12
Description: Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
Study: NCT04022772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study: NCT03967795

Intervention type: DRUG
Group type: OTHER
Intervention: N2-L-Alanyl-L-Glutamine (Substance)
Description: 20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
Study: NCT03816943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whatsapp
Description: a WhatsApp message with encouraging words will be sent after bond up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: a telephone call will be made after bond up to provide encoring words
Study: NCT01590277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Iomazenil
Description: Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Iomazenil
Description: Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 90 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no iomazenil, administered for a total of 10 minutes
Study: NCT04022772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01590277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no iomazenil, administered for a total of 10 minutes
Study: NCT04022772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Participate in PACK Health program
Study: NCT03096093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACIT-1
Description: Cell suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACIT-1
Description: Cell suspension
Study: NCT03811535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Study: NCT02923479

Intervention type: DEVICE
Group type: OTHER
Intervention: Specific ankle rehabilitation by Biodex System 3 dynamometer
Description: Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Specific ankle rehabilitation by ProKin PK254 platform
Description: Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
Study: NCT04288167

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sample collection
Description: Samples of urine and saliva will be collected from participants using customary sample collection means.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Samples of urine and saliva will be collected from participants using customary sample collection means.
Study: NCT00459667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label).
Study: NCT03792308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR206
Description: SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study: NCT02859675

Intervention type: OTHER
Intervention: triangular test
Description: metabolic state, impedance measurement, potential flavours evoked by sucrose,

Intervention type: OTHER
Intervention: triangular test
Description: metabolic state, impedance measurement, potential flavours evoked by sucrose,

Intervention type: OTHER
Intervention: triangular test
Description: metabolic state, impedance measurement, potential flavours evoked by sucrose,

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: sampling of 2 mL

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: sampling of 2 mL

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: sampling of 2 mL
Study: NCT04409691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednison and Sirolimus
Description: If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednison
Description: Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.